Results 31 to 40 of about 1,958,128 (299)

Modelling US health equity impacts of emicizumab for severe haemophilia A: aggregate distributional cost-effectiveness analysis

BMJ Open
Objectives Emicizumab is the first bispecific antibody approved for prophylaxis in people with haemophilia A with or without factor VIII inhibitors. Aggregate distributional cost-effectiveness analysis assesses health equity impacts by evaluating how ...
Randall Curtis, Thomas Majda, Janet S. Lee, Stacey L. Kowal   +3 more
doaj   +1 more source

Factor VIII/V C-domain swaps reveal discrete C-domain roles in factor VIII function and intracellular trafficking

Haematologica, 2017
Factor VIII C-domains are believed to have specific functions in cofactor activity and in interactions with von Willebrand factor. We have previously shown that factor VIII is co-targeted with von Willebrand factor to the Weibel-Palade bodies in blood ...
Eduard H.T.M. Ebberink, Eveline A.M. Bouwens, Esther Bloem, Mariëtte Boon-Spijker, Maartje van den Biggelaar, Jan Voorberg, Alexander B. Meijer, Koen Mertens   +7 more
doaj   +1 more source

Weak proton capture on 3He [PDF]

, 2000
The astrophysical S-factor for the proton weak capture on 3He is calculated with correlated-hyperspherical-harmonics bound and continuum wave functions corresponding to realistic Hamiltonians consisting of the Argonne v14 or Argonne v18 two-nucleon and ...
Beacom, J. F., Kievsky, A., Marcucci, L. E., Rosati, S., Schiavilla, R., Viviani, M.   +5 more
core   +2 more sources

Inhibitor development upon switching from plasma-derived to recombinant factor VIII in previously untreated patients with severe hemophilia A: the PUP-SWITCH study

Research and Practice in Thrombosis and Haemostasis
Background: The SIPPET randomized clinical trial showed that in previously untreated patients (PUPs) with severe hemophilia A, treatment with plasma-derived factor (F)VIII (pdFVIII) within the first 50 exposure days (EDs) was associated with a lower ...
Syna Miri, Frits R. Rosendaal, Kaan Kavakli, Peyman Eshghi, Soha Mohammadi Moghaddam, Sara Scardo, Behnaz Habibpanah, Mohsen Elalfy, Susan Halimeh, Gabriella Nicolò, Dilek Gökçebay, Namık Özbek, Tiraje Celkan, Ahmad Mohammadi, Mehran Karimi, Amin Shahsavani, Bariş Yılmaz, Canan Albayrak, Burcak Gunes, Zühre Kaya, Yilmaz Ay, Sinan Akbayram, Nazan Sarper, Pier Mannuccio Mannucci, Flora Peyvandi   +24 more
doaj   +1 more source

Light-front model of the kaon electromagnetic current [PDF]

, 2002
The electromagnetic form factor is extracted from both components of the electromagnetic current: J(plus) and J(minus) with a pseudo-scalar coupling of the quarks to the kaon.
de Melo, J. P. B. C., Frederico, T., Tomio, Lauro   +2 more
core   +2 more sources

Immunohistochemical characterization of the 'intimal proliferation' phenomenon in Sneddon's syndrome and essential thrombocythaemia [PDF]

, 1994
Cellular changes were immunocytochemically characterized in skin vessels of five patients with idiopathic generalized racemose livedo (Sneddon's syndrome), and one patient with localized racemose livedo associated with essential thrombocythaemia ...
Jungkunz, W., Marsch, W. C., Tamm, Ernst R., Wolter, M.   +3 more
core   +1 more source

N-linked glycosylation modulates the immunogenicity of recombinant human factor VIII in hemophilia A mice

Haematologica, 2018
Immune responses to factor VIII remain the greatest complication in the treatment of severe hemophilia A. Recent epidemiological evidence has highlighted that recombinant factor VIII produced in baby hamster kidney cells is more immunogenic than factor ...
Jesse D. Lai, Laura L. Swystun, Dominique Cartier, Kate Nesbitt, Cunjie Zhang, Christine Hough, James W. Dennis, David Lillicrap   +7 more
doaj   +1 more source

The 1.7 Å X-ray crystal structure of the porcine factor VIII C2 domain and binding analysis to anti-human C2 domain antibodies and phospholipid surfaces. [PDF]

PLoS ONE, 2015
The factor VIII C2 domain is essential for binding to activated platelet surfaces as well as the cofactor activity of factor VIII in blood coagulation. Inhibitory antibodies against the C2 domain commonly develop following factor VIII replacement therapy
Caileen M Brison, Steven M Mullen, Michelle E Wuerth, Kira Podolsky, Matthew Cook, Jacob A Herman, Justin D Walter, Shannon L Meeks, P Clint Spiegel   +8 more
doaj   +1 more source

Angiogenesis in Squamous Cervical Neoplasia: Comparative Study of two Endothelial Cells [PDF]

, 2001
Purpose: to compare the efficiency of anti-factor VIII and anti-CD34 antibodies as vascular makers in cervical cancer, in cervical intraepithelial neoplasia and in normal cervix.
Baracat, Edmund Chada, Calux, Nilciza Maria De Carvalho Tavares, Focchi, João Norberto Stávale Jose, Lima, Geraldo Rodrigues De, Ribalta, Julisa Chamorro Lascasas   +4 more
core   +5 more sources

Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia A: a population pharmacokinetic model

Haematologica, 2020
During factor VIII prophylaxis for severe hemophilia A, bleeding risk increases with time when factor VIII activity is below 1%. Maintaining trough activity above 1% does not protect all patients from bleeding.
Andreas Tiede, Faraizah Abdul Karim, Victor Jiménez-Yuste, Robert Klamroth, Sandra Lejniece, Takashi Suzuki, Andreas Groth, Elena Santagostino   +7 more
doaj   +1 more source